Daiichi Sankyo and its 15,000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical products. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, the Group’s 2025 vision is to become a “Global Pharma Innovator with Competitive Advantage in Oncology”. The European headquarters are in Munich, Germany and we have affiliates in 12 European countries.
